Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Reimbursement May Be Addressed In Tax Bill This Year

Executive Summary

The American Society of Clinical Oncology hopes that a tax bill this fall will be a vehicle for changing the Medicare Part B payment rate for cancer medicines in 2005

You may also be interested in...



Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says

Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology

Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says

Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology

Medicare Cancer Rx Payments Will Be “Disastrous,” Ex-ASCO Head Warns

Oncology drug reimbursement changes mandated by the 2003 Medicare Rx law will cause long term damage to patient care, Memorial Sloan-Kettering Director of Breast Cancer Programs Larry Norton, MD, said June 22 at a Newsweek/Coalition of National Cancer Cooperative Groups panel in Washington, D.C

Related Content

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel